Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells

Biochemical Pharmacology

Volumn 75, Issue 4, 2008, Pages 875-882

  Isenberg, Jeff S ^a   Yu, Christine ^a   Roberts, David D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ABT 510; Cancer; CD36; Fatty acid uptake; Nitric oxide; Thrombospondin 1

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CD36 ANTIGEN; CD36 BINDING PEPTIDE; COLLAGEN; CYCLIC GMP; FATTY ACID; GLYCYLASPARTYLGLYCYLVALYL DEXTRO ISOLEUCYLTHREONYLARGINYLISOLEUCYLARGININE; MYRISTIC ACID; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; NITRIC OXIDE; THROMBIN; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL ADHESION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; FATTY ACID TRANSPORT; HUMAN; HUMAN CELL; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; THROMBOCYTE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD36; CASPASES; CELL ADHESION; CELL LINE; CYCLIC GMP; ENDOTHELIAL CELLS; FATTY ACIDS; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; OLIGOPEPTIDES; PLATELET AGGREGATION; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1;

EID: 38649110737     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.10.025     Document Type: Article

References (39)

1. De Palma M., and Naldini L. Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim Biophys Acta 1766 (2006) 159-166
2. Sata M. Role of circulating vascular progenitors in angiogenesis, vascular healing, and pulmonary hypertension: lessons from animal models. Arterioscler Thromb Vasc Biol 26 (2006) 1008-1014
3. Folkman J., and Angiogenesis. Annu Rev Med 57 (2006) 1-18
4. Roberts D.D. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 10 (1996) 1183-1191
5. Lawler J., and Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 36 (2004) 1038-1045
6. Dawson D.W., Pearce S.F., Zhong R., Silverstein R.L., Frazier W.A., and Bouck N.P. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138 (1997) 707-717
7. Dawson D.W., Volpert O.V., Pearce S.F., Schneider A.J., Silverstein R.L., Henkin J., et al. Three distinct d-amino acid substitutions confer potent anti-angiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 55 (1999) 332-338
8. Reiher F.K., Volpert O.V., Jimenez B., Crawford S.E., Dinney C.P., Henkin J., et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 98 (2002) 682-689
9. Haviv F., Bradley M.F., Kalvin D.M., Schneider A.J., Davidson D.J., Majest S.M., et al. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 48 (2005) 2838-2846
10. Rusk A., Cozzi E., Stebbins M., Vail D., Graham J., Valli V., et al. Cooperative activity of cytotoxic chemotherapy with anti-angiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma. Clin Cancer Res 12 (2006) 7456-7464
11. Quesada A.J., Nelius T., Yap R., Zaichuk T.A., Alfranca A., Filleur S., et al. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ 12 (2005) 649-658
12. Markovic S.N., Suman V.J., Rao R.A., Ingle J.N., Kaur J.S., Erickson L.A., et al. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 30 (2007) 303-309
13. Hoekstra R., de Vos F.Y., Eskens F.A., de Vries E.G., Uges D.R., Knight R., et al. Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination. Eur J Cancer 42 (2006) 467-472
14. Gietema J.A., Hoekstra R., de Vos F.Y., Uges D.R., van der Gaast A., Groen H.J., et al. A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 17 (2006) 1320-1327
15. Jimenez B., Volpert O.V., Reiher F., Chang L., Munoz A., Karin M., et al. c-Jun N-terminal kinase activation is required for the inhibition of neo-vascularization by thrombospondin-1. Oncogene 20 (2001) 3443-3448
16. Westphal J.R. Technology evaluation: ABT-510. Abbott Curr Opin Mol Ther 6 (2004) 451-457
17. Huang H., Campbell S.C., Bedford D.F., Nelius T., Veliceasa D., Shroff E.H., et al. Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510. Mol Cancer Res 2 (2004) 541-550
18. Anderson J.C., Grammer J.R., Wang W., Nabors L.B., Henkin J., Stewart Jr. J.E., et al. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther 6 (2007) 454-462
19. Jimenez B., Volpert O.V., Crawford S.E., Febbraio M., Silverstein R.L., and Bouck N. Signals leading to apoptosis-dependent inhibition of neo-vascularization by thrombospondin-1. Nat Med 6 (2000) 41-48
20. Isenberg J.S., Ridnour L.A., Dimitry J., Frazier W.A., Wink D.A., and Roberts D.D. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 281 (2006) 26069-26080
21. Isenberg J.S., Jia Y., Fukuyama J., Switzer C.H., Wink D.A., and Roberts D.D. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem 282 (2007) 15404-15415
22. Lindberg F.P., Bullard D.C., Caver T.E., Gresham H.D., Beaudet A.L., and Brown E.J. Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice. Science 274 (1996) 795-798
23. Isenberg J.S., Ridnour L.A., Perruccio E.M., Espey M.G., Wink D.A., and Roberts D.D. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA 102 (2005) 13141-13146
24. Roberts D.D., Cashel J., and Guo N. Purification of thrombospondin from human platelets. J Tissue Cult Methods 16 (1994) 217-222
25. Isenberg J.S., Jia Y., Field L., Ridnour L.A., Sparatore A., Del Soldato P., et al. Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid. Br J Pharmacol 151 (2007) 63-72
26. Chang A.C., and Detwiler T.C. Reactions of thrombin-serpin complexes with thrombospondin. Arch Biochem Biophys 299 (1992) 100-104
27. Shaked Y., Bertolini F., Man S., Rogers M.S., Cervi D., Foutz T., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of anti-angiogenesis. Cancer Cell 7 (2005) 101-111
28. Yap R., Veliceasa D., Emmenegger U., Kerbel R.S., McKay L.M., Henkin J., et al. Metronomic low-dose chemotherapy boosts CD95-dependent anti-angiogenic effect of the thrombospondin peptide ABT-510: a complementation anti-angiogenic strategy. Clin Cancer Res 11 (2005) 6678-6685
29. Yang Q., Tian Y., Liu S., Zeine R., Chlenski A., Salwen H.R., et al. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective anti-angiogenesis strategy in neuroblastoma. Cancer Res 67 (2007) 1716-1724
30. Isenberg J.S., Wink D.A., and Roberts D.D. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res 71 (2006) 785-793
31. Radomski M.W., Palmer R.M., and Moncada S. An l-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 87 (1990) 5193-5197
32. Isenberg J.S., Romeo M.J., Yu C., Yu C.K., Nghiem K., Monsale J., et al. Thrombospondin-1 stimulates platelet aggregation by blocking the anti-thrombotic activity of nitric oxide/cGMP signaling. Blood 111 (2008) 613-623
33. Lamy L., Foussat A., Brown E.J., Bornstein P., Ticchioni M., and Bernard A. Interactions between CD47 and thrombospondin reduce inflammation. J Immunol 178 (2007) 5930-5939
34. Rath G.M., Schneider C., Dedieu S., Sartelet H., Morjani H., Martiny L., et al. Thrombospondin-1 C-terminal-derived peptide protects thyroid cells from ceramide-induced apoptosis through the adenylyl cyclase pathway. Int J Biochem Cell Biol 38 (2006) 2219-2228
35. Johansson U., Higginbottom K., and Londei M. CD47 ligation induces a rapid caspase-independent apoptosis-like cell death in human monocytes and dendritic cells. Scand J Immunol 59 (2004) 40-49
36. Roue G., Bitton N., Yuste V.J., Montange T., Rubio M., Dessauge F., et al. Mitochondrial dysfunction in CD47-mediated caspase-independent cell death: ROS production in the absence of cytochrome c and AIF release. Biochimie 85 (2003) 741-746
37. Manna P.P., and Frazier W.A. CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A. Cancer Res 64 (2004) 1026-1036
38. Guo N., Krutzsch H.C., Inman J.K., and Roberts D.D. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57 (1997) 1735-1742
39. Nor J.E., Mitra R.S., Sutorik M.M., Mooney D.J., Castle V.P., and Polverini P.J. Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 37 (2000) 209-218